Editas Medicine, Inc. (NASDAQ:EDIT) Sees Significantly Higher Trading VolumeModern ReadersCRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella an… Continue reading
San Francisco Chronicle |
‘Game-changer’ cancer treatment is focus of Gilead’s $12 billion cell therapy deal
San Francisco Chronicle The deal with Santa Monica’s Kite is expected to close later this year and will intensify competition among major drug companies to introduce a cutting-edge cancer treatment known as CAR T cell therapy. The therapy extracts a patient’s own cells from … New drug price questions loom after Gilead’s cancer purchaseFairfield Daily Republic Gilead’s $11.9 billion purchase of a groundbreaking cancer therapy could drag it into a new debate on pricesWashington Post Here’s How Our Readers Just Scored Big With Immunomedics Inc (NASDAQ:IMMU)Insider Financial |
San Francisco Chronicle |
‘Game-changer’ cancer treatment is focus of Gilead’s $12 billion cell therapy deal
San Francisco Chronicle The deal with Santa Monica’s Kite is expected to close later this year and will intensify competition among major drug companies to introduce a cutting-edge cancer treatment known as CAR T cell therapy. The therapy extracts a patient’s own cells from … New drug price questions loom after Gilead’s cancer purchaseFairfield Daily Republic Gilead’s $11.9 billion purchase of a groundbreaking cancer therapy could drag it into a new debate on pricesWashington Post Analysts Mixed On Gilead-Kite, But One Key Rival Stands To BenefitInvestor’s Business Daily Insider Financial –ClickLancashire all 41 news articles » |
|
2.65k
Scicasts (press release) (blog) Calgary, AB, Canada (Scicasts) — Immunotherapy is an emerging field in the global fight against cancer, even though scientists and clinicians have been working for decades to find ways to help the body’s immune system detect and attack cancerous cells. |
Genetic Engineering & Biotechnology News (press release) |
Will Cell and Gene Therapies Reach a Tipping Point?
Genetic Engineering & Biotechnology News (press release) “With over 750 regenerative medicine firms world-wide, 271 cell and gene therapies in Phase I/II, 66 products in Phase 3, and promising CAR-T cell therapy results and marketed therapies, there’s a lot more optimism now about this sector,” states Kurt … |
Bioscience Technology |
Boosting Immune Cell Memory to Improve Vaccines and Cancer …
Bioscience Technology Drugs that activate cells’ proteasome, or recycling center, generate more memory T cells in mice and cell models. |
|
Immunotherapy that uses existing cancer drugs in a new way delivers promising results
News-Medical.net Immunotherapy is an emerging field in the global fight against cancer, even though scientists and clinicians have been working for decades to find ways to help the body’s immune system detect and attack cancerous cells. Doug Mahoney’s lab at the … |